[go: up one dir, main page]

TN2012000146A1 - Derives de pyrrolo[2,3-d]pyrimidine - Google Patents

Derives de pyrrolo[2,3-d]pyrimidine

Info

Publication number
TN2012000146A1
TN2012000146A1 TNP2012000146A TN2012000146A TN2012000146A1 TN 2012000146 A1 TN2012000146 A1 TN 2012000146A1 TN P2012000146 A TNP2012000146 A TN P2012000146A TN 2012000146 A TN2012000146 A TN 2012000146A TN 2012000146 A1 TN2012000146 A1 TN 2012000146A1
Authority
TN
Tunisia
Prior art keywords
pyrrolo
pyrimidine derivatives
compounds
pyrimidine
jak
Prior art date
Application number
TNP2012000146A
Other languages
English (en)
Inventor
Brad Alan Acker
Susan J Hartmann
Horng-Chih Huang
Eric Jon Jacobsen
Michele Ann Promo
Sergey Gregory Wolfson
Jin Xie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2012000146A1 publication Critical patent/TN2012000146A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés pyrrolo[2,3-d]pyrimidine, leur utilisation comme inhibiteurs de la Janus Kinase (JAK), des compositions pharmaceutiques contenant les composés et leurs procédés de préparation.
TNP2012000146A 2009-10-15 2012-03-29 Derives de pyrrolo[2,3-d]pyrimidine TN2012000146A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15
PCT/IB2010/054447 WO2011045702A1 (fr) 2009-10-15 2010-10-01 Composés pyrrolo[2,3-d]pyrimidine

Publications (1)

Publication Number Publication Date
TN2012000146A1 true TN2012000146A1 (fr) 2013-09-19

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000146A TN2012000146A1 (fr) 2009-10-15 2012-03-29 Derives de pyrrolo[2,3-d]pyrimidine

Country Status (29)

Country Link
US (1) US8633206B2 (fr)
EP (1) EP2488524B1 (fr)
JP (1) JP5629324B2 (fr)
KR (1) KR20120083452A (fr)
CN (1) CN102574860A (fr)
AP (1) AP2012006192A0 (fr)
AR (1) AR078635A1 (fr)
AU (1) AU2010308028A1 (fr)
CA (1) CA2776028C (fr)
CL (1) CL2012000795A1 (fr)
CO (1) CO6531451A2 (fr)
CR (1) CR20120164A (fr)
CU (1) CU20120059A7 (fr)
DO (1) DOP2012000080A (fr)
EA (1) EA201290147A1 (fr)
EC (1) ECSP12011855A (fr)
ES (1) ES2426407T3 (fr)
IL (1) IL218802A0 (fr)
IN (1) IN2012DN02577A (fr)
MA (1) MA33670B1 (fr)
MX (1) MX2012004379A (fr)
NI (1) NI201200053A (fr)
PE (1) PE20121077A1 (fr)
PH (1) PH12012500583A1 (fr)
TN (1) TN2012000146A1 (fr)
TW (1) TWI398444B (fr)
UY (1) UY32947A (fr)
WO (1) WO2011045702A1 (fr)
ZA (1) ZA201202718B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
EP2411393B1 (fr) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Dérivés de pyrimidinediones fusionnés utilisés comme modulateurs des récepteurs trpa1
WO2010109329A1 (fr) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Dérivés de furopyrimidinedione à titre de modulateurs de trpa1
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
EP2513114B1 (fr) * 2009-12-18 2014-04-02 Pfizer Inc. Composés de pyrrolo[2,3-d]pyrimidine
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
RU2632870C2 (ru) 2011-08-12 2017-10-11 Ниссан Кемикал Индастриз, Лтд. Трициклические гетероциклические соединения и ингибиторы jak
WO2014012081A2 (fr) 2012-07-13 2014-01-16 Ontorii, Inc. Contrôle chiral
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
DK2875013T3 (en) * 2012-07-17 2018-01-22 Glaxosmithkline Intellectual Property (No 2) Ltd INDOLECAR CARBON NITRILS AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (fr) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes d'analyse de l'activité jak2 dans des globules rouges sanguins et leurs utilisations
US9475813B2 (en) 2013-02-08 2016-10-25 Nissan Chemical Industries, Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor
PE20151764A1 (es) 2013-02-22 2015-12-03 Pfizer Derivados de pirrolo[2,3-d]pirimidina
PL2991988T3 (pl) * 2013-05-02 2017-10-31 Hoffmann La Roche Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2
EP3095461A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
EP3095460A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
WO2015108048A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
EP2924026A1 (fr) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylméthylcyclohexanes comme inhibiteurs de JAK
MX374105B (es) 2014-05-14 2025-03-05 Nissan Chemical Ind Ltd Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas.
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
US9926327B2 (en) * 2016-02-16 2018-03-27 Zoetis Services Llc Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (fr) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique
EP3610264A1 (fr) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement d'un adénocarcinome canalaire pancréatique
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
PL3915989T3 (pl) 2019-01-30 2023-12-11 Felicamed Biotechnology Co., Ltd Inhibitor jak i sposób jego otrzymywania
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
EP3993793A4 (fr) * 2019-07-01 2023-06-28 Ligang Qian Antagonistes de p2x7r
US12492204B2 (en) 2019-08-26 2025-12-09 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors
WO2021062163A1 (fr) 2019-09-27 2021-04-01 Disc Medicine, Inc. Procédés de traitement de la myélofibrose et d'affections associées
CA3177830A1 (fr) 2020-05-13 2021-11-18 Maria BECONI Anticorps anti-hemojuveline (hjv) pour le traitement de la myelofibrose
CN115246833B (zh) * 2021-04-27 2024-08-13 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
TW505646B (en) * 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
ES2257410T3 (es) * 2000-06-26 2006-08-01 Pfizer Products Inc. Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
BR0316470A (pt) 2002-11-21 2005-10-11 Pfizer Prod Inc Derivados de 3-amino-piperadina e métodos de preparação
CA2536954C (fr) * 2003-08-29 2012-11-27 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
BRPI0416656A (pt) 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
WO2005085253A1 (fr) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Dérivés pyrrolopyrimidine
US7977345B2 (en) * 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
EP2251341A1 (fr) 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
BRPI0613876A2 (pt) 2005-07-29 2011-02-15 Pfizer Prod Inc derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
AU2006297351A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
KR101467723B1 (ko) 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
CA2642229C (fr) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions et methodes destinees a l'inhibition de la voie jak
EP1990335A4 (fr) * 2006-03-02 2009-11-11 Astellas Pharma Inc Inhibiteur de la 17 beta hsd de type 5
WO2009049028A1 (fr) 2007-10-09 2009-04-16 Targegen Inc. Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases
WO2009115084A2 (fr) 2008-03-20 2009-09-24 Schebo Biotech Ag Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
HRP20140395T1 (hr) * 2008-08-20 2014-06-06 Zoetis Llc SPOJEVI PIROLO[2,3-d]PIRIMIDINA

Also Published As

Publication number Publication date
CR20120164A (es) 2012-11-07
MA33670B1 (fr) 2012-10-01
MX2012004379A (es) 2012-06-01
IL218802A0 (en) 2012-06-28
CN102574860A (zh) 2012-07-11
ZA201202718B (en) 2012-12-27
TW201125866A (en) 2011-08-01
KR20120083452A (ko) 2012-07-25
JP2013508266A (ja) 2013-03-07
ES2426407T3 (es) 2013-10-23
CA2776028A1 (fr) 2011-04-21
CL2012000795A1 (es) 2012-09-07
NI201200053A (es) 2012-08-09
EP2488524A1 (fr) 2012-08-22
ECSP12011855A (es) 2012-06-29
US8633206B2 (en) 2014-01-21
CO6531451A2 (es) 2012-09-28
CU20120059A7 (es) 2012-06-29
AP2012006192A0 (en) 2012-04-30
UY32947A (es) 2011-05-31
WO2011045702A1 (fr) 2011-04-21
PH12012500583A1 (en) 2012-10-22
AR078635A1 (es) 2011-11-23
EA201290147A1 (ru) 2012-11-30
PE20121077A1 (es) 2012-08-10
CA2776028C (fr) 2015-12-01
TWI398444B (zh) 2013-06-11
JP5629324B2 (ja) 2014-11-19
US20110136765A1 (en) 2011-06-09
IN2012DN02577A (fr) 2015-08-28
DOP2012000080A (es) 2012-06-15
EP2488524B1 (fr) 2013-07-03
AU2010308028A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MA32341B1 (fr) Dérivés de 3h- [1, 2, 3] triazolo [4, 5, d] pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi3, et leurs synthèses
MX2010009646A (es) Agentes terapeuticos antivirales.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX2011005936A (es) Compuestos organicos.
NZ553405A (en) Nucleoside phosphonate conjugates as anti-HIV agents
MY148634A (en) Pyridazinone derivatives
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
TN2011000244A1 (en) Organic compounds
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2007067506A3 (fr) Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MX2010008719A (es) Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
AU2009282962A8 (en) Compounds as kinase inhibitors
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER